Boston Scientific Remains On Track For Return To Growth By 2021
The company’s sales declined 29% in the second quarter of 2020 due to the pandemic, but sales trends indicate the start of a worldwide recovery across all of Boston Scientific’s businesses.
You may also be interested in...
Boston Scientific’s management believes the ongoing recovery of procedure volumes and new technology will allow it to show revenue growth in the fourth quarter.
The circulatory support device company is transforming into “Abiomed 2.0” by investing in remote monitoring technology as well as online customer service and virtual training programs.
The company recorded $925m in revenue in the second quarter of 2020, exceeding the top end of its previous guidance, and expects to return to growth by the end of the year.